Search tips
Search criteria 


Logo of annaldermaAnnals of DermatologyThis ArticleInformation for AuthorsOnline Submission
Ann Dermatol. Feb 2009; 21(1): 60–62.
Published online Feb 28, 2009. doi:  10.5021/ad.2009.21.1.60
PMCID: PMC2883373
Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease
Byung Cheol Park, M.D.,1 Hyun Jung Lim, M.D., Byung Soo Kim, M.D., Weon Ju Lee, M.D., Do Won Kim, M.D., and Seok-Jong Lee, M.D.corresponding author
Department of Dermatology, Kyungpook National University School of Medicine, Daegu, Korea.
1Department of Dermatology, Ajou University Hospital, Suwon, Korea.
corresponding authorCorresponding author.
Reprint request to: Seok-Jong Lee, M.D., Department of Dermatology, Kyungpook National University School of Medicine, Samduk 2-ga, Jung-gu, Daegu 700-721, Korea. Tel: 82-53-420-5838, Fax: 82-53-426-0770, seokjong/at/
Received June 18, 2008; Accepted August 5, 2008.
As more rheumatologists and dermatologists have begun to use biological agents such as TNF-α blocker, they have confronted an unexpected complication: psoriasis was paradoxically aggravated or induced by the TNF-α blocker. Although it is not a common complication of TNF-α blocker, this aggravation may be more common than previously thought. To our knowledge, most reports about TNF-α blocker-induced psoriasis have been limited to western countries while only a few cases have been reported in Korea and Japan. In addition, new onset of pustular psoriasis by TNF-α blocker has been reported more commonly than worsening of preexisting psoriasis. Now we report a patient whose preexisting psoriasis vulgaris was aggravated repeatedly after using the TNF-α blocker, infliximab, to control Crohn's disease, which is a rare rheumatologic disease in Korea.
Keywords: Aggravation, Crohn's disease, Psoriasis, TNF-α blocker
Articles from Annals of Dermatology are provided here courtesy of
Korean Dermatological Association and Korean Society for Investigative Dermatology